Sec Form 4 Filing - Kroll Werner @ QuidelOrtho Corp - 2022-05-27

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Kroll Werner 2. Issuer Name and Ticker or Trading Symbol QuidelOrtho Corp [ QDEL] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) See Remarks (Last) (First) (Middle) 9975 SUMMERS RIDGE ROAD 3. Date of Earliest Transaction (MM/DD/YY) 05/27/2022 (Street) SAN DIEGO, CA92121 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 05/27/2022 A( 1 ) 18,762 A 18,762 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Non-Qualified Stock Options $ 46.41 05/27/2022 A( 2 ) 2,303 ( 3 ) 01/16/2028 Common Stock 2,303 $ 0 2,303 D Non-Qualified Stock Options $ 59.12 05/27/2022 A( 2 ) 3,924 ( 4 ) 02/04/2029 Common Stock 3,924 $ 0 3,924 D Restricted Stock Units ( 5 ) 05/27/2022 A( 6 ) 3,925 ( 7 ) ( 7 ) Common Stock 3,925 $ 0 3,925 D Restricted Stock Units ( 5 ) 05/27/2022 A( 6 ) 2,743 ( 8 ) ( 8 ) Common Stock 2,743 $ 0 2,743 D Restricted Stock Units ( 5 ) 05/27/2022 A( 6 ) 823 ( 8 ) ( 8 ) Common Stock 823 $ 0 823 D Restricted Stock Units ( 5 ) 05/27/2022 A( 6 ) 4,268 ( 9 ) ( 9 ) Common Stock 4,268 $ 0 4,268 D Restricted Stock Units ( 5 ) 05/27/2022 A( 6 ) 1,962 ( 10 ) ( 10 ) Common Stock 1,962 $ 0 1,962 D Restricted Stock Units ( 5 ) 05/27/2022 A( 6 ) 2,625 ( 11 ) ( 11 ) Common Stock 2,625 $ 0 2,625 D Restricted Stock Units ( 5 ) 05/27/2022 A( 6 ) 3,510 ( 12 ) ( 12 ) Common Stock 3,510 $ 0 3,510 D Restricted Stock Units ( 5 ) 05/27/2022 A( 6 ) 10,642 ( 13 ) ( 13 ) Common Stock 10,642 $ 0 10,642 D Restricted Stock Units ( 5 ) 05/27/2022 A( 6 ) 7,256 ( 14 ) ( 14 ) Common Stock 7,256 $ 0 7,256 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Kroll Werner 9975 SUMMERS RIDGE ROAD SAN DIEGO, CA92121 See Remarks Signatures /s/ Phillip S. Askim, attorney-in-fact for Werner Kroll 06/01/2022 Signature of Reporting Person Date

Explanation of Respo nses:

( 1 )Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho. ( 2 )Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options were converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). ( 3 )Vested in full. ( 4 )5,888 shares are vested in full; 1,962 shares will vest on February 4, 2023. ( 5 )Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. ( 6 )Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). ( 7 )3,925 shares will vest on February 4, 2023. ( 8 )Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule. ( 9 )4,268 shares will vest on February 4, 2023. ( 10 )1,962 shares will vest in equal installments on July 1, 2022 and July 1, 2023. ( 11 )1,312 shares will vest on February 1, 2023; and 1,313 shares will vest on February 1, 2024. ( 12 )3,510 shares will vest in equal installments on July 28, 2022, July 28, 2023 and July 28, 2024. ( 13 )3,547 shares will vest on each of January 31, 2023 and January 31, 2024; 3,548 shares will vest on January 31, 2025. ( 14 )3,628 shares will vest on January 31, 2024; the remaining 3,628 shares will vest in equal installments on January 31, 2025 and January 31, 2026.

Remarks: SVP, Research and Development

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.